MARKET

MRNA

MRNA

Moderna
NASDAQ

Real-time Quotes | Nasdaq Last Sale

141.01
-11.73
-7.68%
Pre Market: 150.03 +9.02 +6.40% 04:22 12/02 EST
OPEN
177.66
PREV CLOSE
152.74
HIGH
178.50
LOW
130.33
VOLUME
26.84K
TURNOVER
--
52 WEEK HIGH
178.50
52 WEEK LOW
17.68
MARKET CAP
55.80B
P/E (TTM)
-87.1185
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Roche's coronavirus antibody test gets emergency use authorization from the U.S.
Roche has received emergency use authorization from the U.S. Food and Drug Administration (FDA) for a new test that measures levels of Covid-19 antibodies.
CNBC.com · 1h ago
Pfizer-BioNTech COVID-19 Vaccine Gets UK Approval For Emergency Use
Pfizer Inc (NYSE: PFE) and its German partner BioNTech SE (NASDAQ: BNTX) said Wednesday they have received regulatory approval in the United Kingdom for their COVID-19 vaccine.
Benzinga · 1h ago
U.K. becomes first country to authorize Pfizer-BioNTech vaccine for emergency use
Pfizer (PFE) and BioNTech (BNTX) have won permission for emergency use of their COVID-19 vaccine in Britain, with two doses three weeks apart required for protection. First in line are
Seekingalpha · 1h ago
Gold edges down on vaccine prospects; investors eye stimulus
Gold prices edged lower on Wednesday on growing progress over a coronavirus vaccine to aid a swift global economic recovery, with investors eyeing the possibility for further U.S. stimulus.
Reuters · 7h ago
CDC panel recommends health care staff and long term facility residents receive first COVID-19 vaccines
CDC advisory committee votes on COVID-19 vaccine allotment as soon as emergency use authorization granted.
Yahoo Finance · 10h ago
Health-Care Workers and Long-Term Care Residents Should Get Covid Shots First, CDC Says
The manufacturers say they’ll be able to deliver about 40 million doses of the two-shot vaccines by year end.
Barrons.com · 10h ago
Moderna jumps for a second straight day
Jared Holz, Jefferies, on Moderna's stock move. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Brian Kelly, Karen Finerman and James McDonald.
CNBC.com · 10h ago
CDC advisors prioritize health workers, nursing home residents for vaccines
CNBC's Meg Tirrell reports the CDC has determined who should be prioritized as the first groups to get the coronavirus vaccine. With CNBC's Melissa Lee and the Fast Money traders, Guy Adami, Brian Kelly, Karen Finerman and James McDonald.
CNBC.com · 10h ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRNA. Analyze the recent business situations of Moderna through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MRNA stock price target is 119.60 with a high estimate of 185.00 and a low estimate of 60.00.
EPS
Institutional Holdings
Institutions: 662
Institutional Holdings: 203.49M
% Owned: 51.42%
Shares Outstanding: 395.71M
TypeInstitutionsShares
Increased
205
13.05M
New
214
-1.99M
Decreased
132
25.51M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.30%
Pharmaceuticals & Medical Research
+0.62%
Key Executives
Non-Executive Chairman/Co-Founder/Independent Director
Noubar Afeyan
President
Stephen Hoge
Chief Executive Officer/Director
Stephane Bancel
Chief Financial Officer
David Meline
Chief Human Resource Officer
Tracey Franklin
Chief Technology Officer
Juan Andres
General Counsel/Secretary
Lori Henderson
Other
Marcello Damiani
Other
Tal Zaks
Other
Ray Jordan
Other
Tal Zvi Zaks
Director
Elizabeth Tallett
Non-Executive Independent Director
Stephen Berenson
Non-Executive Independent Director
Robert Langer
Non-Executive Independent Director
Francois Nader
Non-Executive Independent Director
Israel Ruiz
Non-Executive Independent Director
Paul Sagan
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRNA
Moderna, Inc. is engaged in transformative medicines based on messenger ribonucleic acid (mRNA). It has created a platform to improve the underlying pharmaceutical properties of our mRNA medicines. Its platform consists of three areas: mRNA technologies, delivery technologies, and manufacturing processes. It is pursuing mRNA science to minimize the undesirable activation of the immune system by mRNA and to maximize the potency of mRNA once in the target cells. It has advanced in parallel a diverse development pipeline of 21 programs, of which 10 have entered clinical studies and another three have open INDs. Its therapeutics and vaccine development programs span infectious diseases, oncology, cardiovascular diseases, and rare genetic diseases. It has created six modalities prophylactic vaccines, cancer vaccines, intratumoral immmuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics and systemic intracellular therapeutics.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Moderna Inc stock information, including NASDAQ:MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.